ABSTRACT Background/Objective. The 21-gene Oncotype DX Ò Breast Recurrence Score Ò (RS) assay has been prospectively validated as prognostic and predictive in nodenegative, estrogen receptor-positive (ER?)/HER2-breast cancer patients. Less is known about its prognostic role in node-positive breast cancer. We compared RS results among patients with lymph node-negative (N0), micrometastatic (N1mi), and macrometastatic (N?) breast cancer to determine if nodal metastases are associated with more aggressive biology, as determined by RS. Methods. Overall, 610,350 tumor specimens examined by the Genomic Health laboratory from February 2004 to August 2017 were studied. Histology was classified centrally, while lymph node status was determined locally. RS distribution (low: \ 18; intermediate: 18-30; high: C 31) was compared by nodal status. Results. Eighty percent (n = 486,013) of patients were N0, 4% (n = 24,325) were N1mi, 9% (n = 56,100) were N?, and 7% (n = 43,912) had unknown nodal status. Mean RS result was 18, 16.7, 17.3 and 18.9 in the N0, N1mi, N?, and unknown groups, respectively. An RS C 31 was seen in 10% of N0 patients, 7% of N1mi patients, and 8.0% of N? patients. The likelihood of an RS C 31 in N1mi and N? patients varied with tumor histology, with only 2% of patients with classic infiltrating lobular cancer having an RS C 31, versus 7-9% of those with ductal carcinoma.
Conclusions. RS distribution among N0, N1mi, and N? patients is similar, suggesting a spectrum of biology and potential chemotherapy benefit exists among node-negative and node-positive ER?/HER2-breast cancer patients. If RxPONDER does not show a chemotherapy benefit in N? patients with a low RS result, our findings indicate that substantial numbers of patients could be spared the burden of chemotherapy.
Lymph node status in breast cancer has historically been considered the most important prognostic factor determining disease-specific and overall survival. Demonstration in the Early Breast Cancer Trialists' Collaborative Group overview analysis that the combination of chemotherapy and hormonal therapy halved the risk of breast cancer mortality in women with estrogen receptorpositive (ER?) cancers led this treatment to be considered standard in patients with node-positive breast cancer. [1] [2] [3] However, it is recognized that not all ER? patients derive the same benefit from adjuvant chemotherapy. 4, 5 More recently, molecular assays such as the Oncotype DX 21-gene Breast Cancer Recurrence Score Ò (RS) [Genomic Health, Redwood City, CA, USA] have been shown to more reliably predict prognosis than standard histopathologic features in hormone receptor-positive (HR?)/HER2-negative (HER2-) breast cancer patients with and without axillary nodal metastases treated with endocrine therapy. [6] [7] [8] [9] [10] [11] The excellent prognosis for nodenegative patients with low RS results after treatment with endocrine therapy alone has been demonstrated in a prospective study and in population-based registries. 12, 13 A retrospective analysis of the National Surgical Adjuvant Breast and Bowel Project (NSABP) B20 trial suggests that the RS result also predicts the benefit of chemotherapy in node-negative women, and this hypothesis was prospectively confirmed in the TAILORx study.
14 Both National Comprehensive Cancer Network (NCCN) and American Society of Clinical Oncology (ASCO) guidelines recommend the use of the RS assay in patients with ER?/ HER2-, lymph node-negative, or micrometastatic tumors [ 5 mm in size. The role of the RS result in patients with nodal metastases has been examined using archived tumors from clinical trials, and the results are similar to those seen in node-negative patients. 6, 7 However, patients with nodal metastases have been studied in much more limited numbers, and it is unclear if the same spectrum of low-and high-risk RS results exists among node-positive patients.
The purpose of this study was to compare RS results among patients with lymph node-negative (N0), micrometastatic (N1mi), and macrometastatic (N?) breast cancer to determine if the distribution of RS results varies with nodal status.
METHODS
A total of 619,866 invasive breast cancer specimens examined in the Genomic Health clinical laboratory in the United States from February 2004 to August 2017 were identified. After exclusion of 9516 samples due to missing histologic subtype (n = 9284) or recording of more than one histologic subtype (n = 232), 610,350 tumor specimens comprised the study population. Using World Health Organization criteria, histologic subtype was classified centrally by board-certified surgical pathologists after review of a single hematoxylin and eosin slide. 15 Lymph node status was determined by local review, and patients were classified as having lymph node negative (N0), micrometastatic (N1mi), or macrometastatic (N?) nodal disease. 16 Invasive breast cancer tumor specimens classified as ductal, lobular (classic or other variants), mixed ductal/lobular, tubular, papillary, mucinous, and cribriform were included in this study.
The Oncotype DX 21-gene Breast Recurrence Score Ò algorithm is based on quantitative expression of 16 cancerrelated genes and 5 reference genes, which has been previously described. 17 The expression of these genes is measured in triplicate using reverse transcription polymerase chain reaction (RT-PCR) from formalin-fixed, paraffin-embedded tumor tissue. RS results range from 0 to 100, where a higher score indicates an increased risk of recurrence.
Institutional Review Board approval was waived due to the de-identified nature of this outside dataset.
Statistical Analysis
Descriptive statistics were calculated for the RS result based on originally reported cut-offs (low: \ 18; intermediate: 18-30; high: C 31), as well as the cut-off points used for the RxPONDER (low: B 25; high: [ 25) clinical trial. 10 RS distribution was analyzed by histologic subtype and nodal status. Continuous variables are reported as the mean, median, and interquartile range (IQR). Because of the large study sample size, all analyses are descriptive since even small differences between groups were expected to be statistically significant, but potentially not clinically meaningful. All analyses were performed on de-identified data.
RESULTS
A total of 610,350 breast cancer specimens were included in the study. The majority of patients were node negative (80%, n = 486,013); 4% (n = 24,325) had micrometastatic disease (N1mi), 9% (n = 56,100) had macrometastases (N?), and 7% (n = 43,912) had unknown nodal status (not reported to Genomic Health or nodes not sampled). The median patient age was 60 years (IQR 51-67) in N0 and N1mi patients, 62 years in N? patients (IQR 52-70), and 61 years in patients with unknown nodal status (IQR 52-68). Patients older than 50 years of age comprised 76% (n = 371,283), 77% (n = 18,665), 81% (n = 45,553), and 78% (n = 34,393) of patients in the N0, N1mi, N?, and unknown nodal groups, respectively.
The mean RS result was similar across nodal subgroups; 18.0 in the N0 group, 16.7 in the N1mi group, 17.3 in the N? group, and 18.9 in the unknown group. The majority of patients in all nodal subgroups had an RS \ 18 (Table 1 ). An RS \ 18 was seen in 59% (n = 286,504/486,013) of N0 patients, 64% (n = 15,463/24,325) of N1mi patients, and 62% (n = 34,603/56,100) of N? patients. Similarly, there was little variation in the rate of RS C 31 based on nodal status (Fig. 1) .
When results were examined using the cut-offs for the RxPONDER trial, the majority of patients remained in the low-risk (RS B 25) group. An RS C 25 was recorded in 83% (n = 403,944) of N0 patients, 87% (n = 21,052) of N1mi patients, and 85% (n = 47,819) of N? patients, while the rate of RS [ 25 was 17, 13 and 15% in the N0, N1mi, and N? patients, respectively (Fig. 1) .
The rates of nodal macrometastases among histologic subtypes ranged from 4% to 12%, with macrometastases most frequent in carcinoma of mixed ductal and lobular histology (12%), lobular carcinoma, of classic type (11%), and infiltrating ductal carcinoma, not otherwise specified (NOS; 9%). As expected, macrometastases were infrequent among the tumors of special histologic subtype, being present in 3% of tubular cancers and 4% of mucinous and papillary cancers. The distribution of mean RS results according to nodal status and histologic subtype is shown in Table 2 . Even after controlling for histology, mean RS results did not vary substantially by nodal status. For example, in the infiltrating ductal NOS group, mean RS results for node-negative, micrometastatic, macrometastatic, and unknown nodal status patients were 18.5, 17, 17.6, and 19.4, respectively. In the mucinous carcinoma patients, RS results for node-negative, micrometastatic, macrometastatic, and unknown nodal status were 14.9, 14.8, 15, and 15, respectively.
Greater variation in the proportion of patients having high RS results was seen based on histology rather than nodal status. An RS C 31 was present in 11% of patients with infiltrating ductal carcinomas NOS, 4% of those with mucinous carcinomas, and 0.5% of those with tubular carcinoma. Within the ductal group, the proportion of patients with an RS C 31 was 11% for N0 patients and 9% for N? patients. For those with mucinous carcinoma, 4% of patients with either N0 or N? had high RS results, while for those with tubular carcinoma, an RS C 31 was seen in 0.4% of N0 patients and 0.8% of N? patients (Table 3) . Using the RxPONDER cut-off of an RS [ 25 to define the high-risk group, similar results were seen with greater variation based on histology rather than nodal status (data not shown). For either the standard cut-points or the RxPONDER cut-points, histologies associated with a favorable prognosis, such as tubular, mucinous, cribriform, and papillary, infrequently had high RS results, regardless RS recurrence score, NOS not otherwise specified, N0 node negative, N1mi micrometastatic, N? macrometastatic of nodal status, and the frequency of high RS results also did not vary based on nodal status among the more common ductal and lobular cancers.
DISCUSSION
Incorporation of the RS result into clinical decision making has led to dramatic reductions in chemotherapy use among patients with node-negative breast cancer. [18] [19] [20] [21] In this study evaluating RS results among N0, N1mi, and N? patients, RS results were similar among patients with and without nodal metastases, suggesting that just as the RS result identifies a spectrum of biology and predicts benefit of chemotherapy among ER?/HER2, N0 patients, the same biologic spectrum exists within patients with nodal metastases.
Multiple studies have demonstrated the prognostic value of the RS assay in ER?/HER2-patients with one to three nodal metastases. Dowsett et al. examined RS results in both node-positive and node-negative postmenopausal women using samples from the tamoxifen and anastrozole treatment arms of the Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trial and showed that the RS result was significantly associated with the risk of distant recurrence in women with and without nodal metastases. The 9-year distant recurrence rates after treatment with endocrine therapy alone in the low (\ 18), intermediate (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) (28) (29) (30) , and high (C 31) RS groups were 4%, 12%, and 25%, respectively, in N0 patients, and 17%, 28%, and 49%, respectively, in patients with any number of positive nodes. In each of the RS groups, the risk of distant recurrence was higher in node-positive patients than node-negative patients, emphasizing that nodal status remains an independent prognostic factor; however, only 306 nodepositive patients were included in that study. 22 A previous analysis of the Genomic Health database by Swain et al. examining over 394,000 patients, including over 30,000 N? patients, showed that the distribution of the RS result in patients with one to three nodal metastases was similar to that of N0 patients, with 61% having a low RS versus 58%, and 7% versus 8.5% with a high RS, respectively. 23 These data are comparable to our results using a larger cohort of 610,350 patients, including over 43,000 patients with N? disease. In our study, 62% of N? patients had a low RS, compared with 59% of N0 patients, and 8% of N? patients versus 10% of N0 patients had a high RS. 12, 24 Among the 6768 patients with nodal metastases, clinical and pathologic features were comparable with those in the SEER N0 cohort; most tumors were 1-2 cm in size and grade 2. Micrometastases were present in 42% of patients. In the remaining patients, 39% had one positive node, 11% had two positive nodes, and 4% had three positive nodes. The majority of patients with micrometastases (58%) or involvement of one to three nodes with metastases had an RS \ 18. For those with one involved node, 59% had an RS \ 18, compared with 51% of patients with three involved nodes. In those with involvement of four or more nodes (n = 285), only 45% had an RS \ 18. A similar pattern was seen for RS C 31, which increased from 7% in patients with one nodal metastases, to 11% in those with three nodal metastases and 14% in those with four or more metastases. These data parallel our results in a larger population, with 64% of patients with micrometastases and 62% of the group with macrometastases having an RS \ 18.
The studies discussed above support our finding that the distribution of the RS results between patients with N0, N1mi, and N? disease is similar, with the majority having an RS \ 18 12, 23, 24 One possible explanation for this is the selection of node-positive patients with favorable histologic features to undergo the RS test. To address this issue, we examined RS results by histology. An RS C 31 was similar among N0 and N? patients after stratification by subtype, even among the 504,362 patients with infiltrating ductal carcinoma NOS, indicating that this finding was not solely due to enrichment of the N? group with tumors of RS recurrence score, NOS not otherwise specified, N0 node negative, N? macrometastatic favorable histologies. Additionally, the distribution of nodal metastases varied by histologic subtype, as would be anticipated, being three to four times more common in the ductal, lobular, and mixed ductal and lobular carcinomas than in the tubular, mucinous, and papillary carcinomas, further suggesting that our findings cannot solely be attributed to selection bias. Both SEER studies examining survival outcomes in N0 and N? patients have demonstrated that RS was significantly associated with 5-year breast cancer-specific mortality (BCSM) in N1mi and N? patients. Notably, 5-year BCSM was 1.3% or lower for patients with RS results \ 18, regardless of nodal status. The unadjusted 5-year BCSM rates for an RS \ 18, RS 18-30, and RS C 31 in node-positive patients were 1.0%, 2.3%, and 14.3%, respectively. 12 Of note, the 5-year BCSM for the 21,000? N0 patients with an RS \ 18 was 0.4%, emphasizing that while our study does not demonstrate a difference in the distribution of RS results based on nodal status, nodal status remains an important prognostic factor in breast cancer. 12 Similarly, the West German Study Group Plan B study showed a 5-year disease-free survival of 94% in N0 patients and those with involvement of one to three nodes and an RS result of B 11 treated with hormone therapy alone. 25 In patients with node-negative breast cancer, the major clinical utility of the RS result is the identification of patients with a good prognosis who do not benefit from the addition of chemotherapy to endocrine therapy. A retrospective analysis of RS results in 367 of the 927 N? postmenopausal patients enrolled in the Southwest Oncology Group (SWOG) S8814 study, which demonstrated improved survival with the addition of cyclophosphamide, doxorubicin, and fluorouracil (CAF) to tamoxifen, suggests a similar predictive role in N? women. In this study, N? patients with an RS \ 18 derived no benefit from the addition of chemotherapy to tamoxifen, whereas patients with an RS C 31 had a 25% improvement in breast cancerspecific survival when treated with chemotherapy. 7 Although the Trans-ATAC 22 , Plan B, 26 and SWOG S8814 7 analyses indicate that the RS result is prognostic in N? patients, and the SWOG S8814 trial 7 suggests that it is predictive of the benefit of chemotherapy, this question is being definitively addressed in the RxPONDER trial in which women with ER?/HER2-breast cancer with one to three positive nodes and an RS result B 25 are randomized to receive adjuvant endocrine therapy with or without chemotherapy. If the RxPONDER trial demonstrates no benefit for chemotherapy in the RS B 25 group, the findings of our study demonstrating that a large proportion of women with nodal metastases have low RS results suggests that a substantial number of N? women can be treated with endocrine therapy alone.
The strengths of our study include the very large sample size of more than 55,000 N? patients and 24,000 N1mi patients, and the ability to examine RS results by histologic subtype. One potential weakness is that our findings may reflect the selection of more favorable N? patients for the RS assay. However, the large sample size and consistency of results across tumor subtypes support the finding that there may be significant numbers of women with N? disease at low risk for recurrence after treatment with endocrine therapy alone. Other limitations of our analysis include the absence of treatment information, other clinicopathologic characteristics (e.g. race, size, and grade), and clinical outcomes.
CONCLUSIONS
Our study indicates that RS results among N0, N1mi, and N? patients are similar, suggesting that just as the RS identifies a spectrum of biology and predicts benefit of chemotherapy among ER?/HER2-, N0 patients, the same biologic spectrum exists within patients with nodal metastases. If the RxPONDER trial demonstrates a predictive benefit for the RS result in N? women, our findings suggest that substantial numbers of patients could be spared the burden of chemotherapy. 
